REAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
5PSQ-037
PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER
5PSQ-036
ANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT
5PSQ-035
SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY
5PSQ-034
COMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER
5PSQ-033
TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE
5PSQ-032
USE OF THE "PRECAUTIONARY ANNULMENTS" TOOL BY A HOSPITAL PHARMACY SERVICE
5PSQ-031
"ASSESSING HEALTHCARE PROFESSIONALS "VIEWS ON DEPRESCRIPTION
5PSQ-030
CONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT
5PSQ-029
THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS
5PSQ-028
CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA
5PSQ-027
VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS
5PSQ-026
THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS
5PSQ-025
AUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION
5PSQ-024
ENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL
